Cipher Pharmaceuticals Inc. (NASDAQ:CPHR) – Equities research analysts at Cormark dropped their Q3 2016 earnings per share (EPS) estimates for Cipher Pharmaceuticals in a research note issued on Monday. Cormark analyst D. Novak now expects that the brokerage will earn ($0.10) per share for the quarter, down from their previous estimate of ($0.05). Cormark also issued estimates for Cipher Pharmaceuticals’ Q4 2016 earnings at ($0.06) EPS and FY2016 earnings at ($0.39) EPS.
A number of other research analysts have also weighed in on the stock. GMP Securities reaffirmed a “hold” rating on shares of Cipher Pharmaceuticals in a research note on Saturday, August 13th. TD Securities reaffirmed a “buy” rating and issued a $7.50 price target on shares of Cipher Pharmaceuticals in a research note on Saturday, August 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Cipher Pharmaceuticals has an average rating of “Hold” and an average target price of $6.85.
Cipher Pharmaceuticals (NASDAQ:CPHR) opened at 3.75 on Wednesday. The firm’s market cap is $98.23 million. Cipher Pharmaceuticals has a 52 week low of $3.55 and a 52 week high of $6.37. The stock’s 50 day moving average is $4.01 and its 200 day moving average is $5.08.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
Receive News & Ratings for Cipher Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.